
Ethynylated Duplex Drugs: Advancing Cancer Therapy Solutions

Our invention describes so called duplex drugs by using phosphodiester bounding as a linker between two nucleoside analogues. Their in vivo metabolism delivers a mixture of highly active antimetabolites. First experimental data demonstrate advantages of our duplex drugs compared to classical nucleoside analogues against some types of cancer cells.
Further Information: PDF
Eberhard Karls Universität Tübingen
Phone: +49 (7071) 29-72639
Contact
Dr. Rolf Hecker